Clinical outcomes for transplant recipients stratified by median numbers of CD4+T cells and CD4+T-cell subsets
| . | Greater than or equal to the median . | Less than the median . | P . |
|---|---|---|---|
| Total CD4+ T cells | ≥109/μL | <109/μL | |
| OS in all patients | |||
| No. evaluated | 138 | 138 | .05 |
| At 3 mo | 96 (92-98) | 88 (83-93) | .02 |
| At 6 mo | 85 (78-90) | 75 (67-82) | .03 |
| At 12 mo | 76 (69-83) | 62 (53-70) | .009 |
| At 24 mo | 62 (54-70) | 47 (39-55) | .01 |
| OS in BM recipients | |||
| No. evaluated | 40 | 84 | .30 |
| At 3 mo | 95 (86-100) | 92 (85-97) | .47 |
| At 6 mo | 85 (72-94) | 77 (68-86) | .29 |
| At 12 mo | 72 (58-85) | 67 (56-76) | .52 |
| At 24 mo | 59 (44-74) | 50 (39-61) | .32 |
| OS in G-PB recipients | |||
| No. evaluated | 98 | 54 | .05 |
| At 3 mo | 96 (91-99) | 83 (72-92) | .02 |
| At 6 mo | 85 (77-91) | 70 (58-82) | .05 |
| At 12 mo | 78 (69-85) | 54 (40-67) | .003 |
| At 24 mo | 63 (54-72) | 43 (30-56) | .01 |
| Grade 2-4 aGVHD in all patients | |||
| No evaluated | 138 | 138 | .40 |
| At 3 mo | 43 (35-52) | 41 (33-50) | .71 |
| At 6 mo | 51 (42-59) | 46 (37-54) | .40 |
| Grade 3-4 aGVHD in all patients | |||
| No. evaluated | 138 | 138 | .10 |
| At 3 mo | 10 (4-18) | 3 (0-10) | .13 |
| At 6 mo | 10 (4-18) | 3 (0-10) | .13 |
| cGVHD in all patients | |||
| No. evaluated | 138 | 138 | .005 |
| At 3 mo | 4 (2-8) | 4 (1-7) | .76 |
| At 6 mo | 30 (22-38) | 23 (17-31) | .22 |
| At 12 mo | 58 (50-66) | 41 (33-49) | .003 |
| At 24 mo | 67 (59-74) | 48 (40-56) | .001 |
| Relapse in all patients | |||
| No. evaluated | 138 | 138 | .58 |
| At 3 mo | 10 (6-16) | 10 (6-16) | 1.00 |
| At 6 mo | 18 (12-25) | 20 (14-27) | .65 |
| At 12 mo | 23 (17-31) | 27 (20-34) | .49 |
| At 24 mo | 28 (21-36) | 30 (23-38) | .70 |
| TRM | |||
| No. evaluated | 138 | 138 | .11 |
| At 3 mo | 3 (1-6) | 10 (6-16) | .01 |
| At 6 mo | 8 (4-13) | 15 (10-22) | .06 |
| At 12 mo | 12 (7-17) | 21 (15-28) | .03 |
| At 24 mo | 17 (11-23) | 27 (20-34) | .04 |
| OS based upon CD4+ T-cell subsets | |||
| Naive CD4+ T cells in all patients | ≥9/μL | <9/μL | |
| No. evaluated | 135 | 134 | .23 |
| At 3 mo | 96 (92-99) | 87 (81-93) | .007 |
| At 6 mo | 84 (78-90) | 76 (69-83) | .08 |
| At 12 mo | 75 (67-82) | 63 (55-71) | .04 |
| At 24 mo | 61 (52-69) | 52 (44-60) | .15 |
| Central memory CD4+ T cells in all patients | ≥21/μL | <21/μL | |
| No. evaluated | 135 | 134 | .86 |
| At 3 mo | 93 (89-97) | 90 (85-95) | .36 |
| At 6 mo | 81 (75-88) | 79 (72-86) | .62 |
| At 12 mo | 70 (62-77) | 69 (61-76) | .87 |
| At 24 mo | 58 (50-67) | 54 (46-63) | .52 |
| Effector memory CD4+ T cells in all patients | ≥39/μL | <39/μL | |
| No. evaluated | 135 | 134 | .05 |
| At 3 mo | 96 (88-97) | 88 (86-95) | .02 |
| At 6 mo | 85 (75-88) | 75 (72-86) | .04 |
| At 12 mo | 75 (62-77) | 63 (59-75) | .04 |
| At 24 mo | 63 (50-66) | 50 (46-62) | .03 |
| Terminal effector CD4+ T cells in all patients | ≥1/μL | <1/μL | |
| No. evaluated | 135 | 134 | 1.00 |
| At 3 mo | 93 (89-97) | 90 (85-95) | .36 |
| At 6 mo | 81 (74-87) | 80 (73-86) | .85 |
| At 12 mo | 67 (59-75) | 71 (63-78) | .53 |
| At 24 mo | 58 (50-67) | 55 (467-63) | .52 |
| CD4+ Tregs in all patients | ≥28/μL | <28/μL | |
| No. evaluated | 140 | 138 | .62 |
| At 3 mo | 93 (88-97) | 90 (84-94) | .37 |
| At 6 mo | 81 (75-87) | 77 (69-83) | .34 |
| At 12 mo | 72 (64-79) | 64 (56-72) | .17 |
| At 24 mo | 56 (48-65) | 52 (43-60) | .46 |
| . | Greater than or equal to the median . | Less than the median . | P . |
|---|---|---|---|
| Total CD4+ T cells | ≥109/μL | <109/μL | |
| OS in all patients | |||
| No. evaluated | 138 | 138 | .05 |
| At 3 mo | 96 (92-98) | 88 (83-93) | .02 |
| At 6 mo | 85 (78-90) | 75 (67-82) | .03 |
| At 12 mo | 76 (69-83) | 62 (53-70) | .009 |
| At 24 mo | 62 (54-70) | 47 (39-55) | .01 |
| OS in BM recipients | |||
| No. evaluated | 40 | 84 | .30 |
| At 3 mo | 95 (86-100) | 92 (85-97) | .47 |
| At 6 mo | 85 (72-94) | 77 (68-86) | .29 |
| At 12 mo | 72 (58-85) | 67 (56-76) | .52 |
| At 24 mo | 59 (44-74) | 50 (39-61) | .32 |
| OS in G-PB recipients | |||
| No. evaluated | 98 | 54 | .05 |
| At 3 mo | 96 (91-99) | 83 (72-92) | .02 |
| At 6 mo | 85 (77-91) | 70 (58-82) | .05 |
| At 12 mo | 78 (69-85) | 54 (40-67) | .003 |
| At 24 mo | 63 (54-72) | 43 (30-56) | .01 |
| Grade 2-4 aGVHD in all patients | |||
| No evaluated | 138 | 138 | .40 |
| At 3 mo | 43 (35-52) | 41 (33-50) | .71 |
| At 6 mo | 51 (42-59) | 46 (37-54) | .40 |
| Grade 3-4 aGVHD in all patients | |||
| No. evaluated | 138 | 138 | .10 |
| At 3 mo | 10 (4-18) | 3 (0-10) | .13 |
| At 6 mo | 10 (4-18) | 3 (0-10) | .13 |
| cGVHD in all patients | |||
| No. evaluated | 138 | 138 | .005 |
| At 3 mo | 4 (2-8) | 4 (1-7) | .76 |
| At 6 mo | 30 (22-38) | 23 (17-31) | .22 |
| At 12 mo | 58 (50-66) | 41 (33-49) | .003 |
| At 24 mo | 67 (59-74) | 48 (40-56) | .001 |
| Relapse in all patients | |||
| No. evaluated | 138 | 138 | .58 |
| At 3 mo | 10 (6-16) | 10 (6-16) | 1.00 |
| At 6 mo | 18 (12-25) | 20 (14-27) | .65 |
| At 12 mo | 23 (17-31) | 27 (20-34) | .49 |
| At 24 mo | 28 (21-36) | 30 (23-38) | .70 |
| TRM | |||
| No. evaluated | 138 | 138 | .11 |
| At 3 mo | 3 (1-6) | 10 (6-16) | .01 |
| At 6 mo | 8 (4-13) | 15 (10-22) | .06 |
| At 12 mo | 12 (7-17) | 21 (15-28) | .03 |
| At 24 mo | 17 (11-23) | 27 (20-34) | .04 |
| OS based upon CD4+ T-cell subsets | |||
| Naive CD4+ T cells in all patients | ≥9/μL | <9/μL | |
| No. evaluated | 135 | 134 | .23 |
| At 3 mo | 96 (92-99) | 87 (81-93) | .007 |
| At 6 mo | 84 (78-90) | 76 (69-83) | .08 |
| At 12 mo | 75 (67-82) | 63 (55-71) | .04 |
| At 24 mo | 61 (52-69) | 52 (44-60) | .15 |
| Central memory CD4+ T cells in all patients | ≥21/μL | <21/μL | |
| No. evaluated | 135 | 134 | .86 |
| At 3 mo | 93 (89-97) | 90 (85-95) | .36 |
| At 6 mo | 81 (75-88) | 79 (72-86) | .62 |
| At 12 mo | 70 (62-77) | 69 (61-76) | .87 |
| At 24 mo | 58 (50-67) | 54 (46-63) | .52 |
| Effector memory CD4+ T cells in all patients | ≥39/μL | <39/μL | |
| No. evaluated | 135 | 134 | .05 |
| At 3 mo | 96 (88-97) | 88 (86-95) | .02 |
| At 6 mo | 85 (75-88) | 75 (72-86) | .04 |
| At 12 mo | 75 (62-77) | 63 (59-75) | .04 |
| At 24 mo | 63 (50-66) | 50 (46-62) | .03 |
| Terminal effector CD4+ T cells in all patients | ≥1/μL | <1/μL | |
| No. evaluated | 135 | 134 | 1.00 |
| At 3 mo | 93 (89-97) | 90 (85-95) | .36 |
| At 6 mo | 81 (74-87) | 80 (73-86) | .85 |
| At 12 mo | 67 (59-75) | 71 (63-78) | .53 |
| At 24 mo | 58 (50-67) | 55 (467-63) | .52 |
| CD4+ Tregs in all patients | ≥28/μL | <28/μL | |
| No. evaluated | 140 | 138 | .62 |
| At 3 mo | 93 (88-97) | 90 (84-94) | .37 |
| At 6 mo | 81 (75-87) | 77 (69-83) | .34 |
| At 12 mo | 72 (64-79) | 64 (56-72) | .17 |
| At 24 mo | 56 (48-65) | 52 (43-60) | .46 |
Transplant patients were stratified into 2 groups based upon blood levels of CD4+ T cells above or below the median at 1 month posttransplant, and the frequency (%) of clinical events of interest (survival, grade 2-4 aGVHD, cGVHD, relapse, and TRM) were calculated at 3, 6, 12, and 24 months with 95% confidence intervals in parentheses. Numbers of evaluable samples analyzed for each immune cell subset are shown. Comparisons with P ≤ .01 were considered significant.